Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Stock Information for Fortress Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.